Home/Filings/4/0001415889-25-019108
4//SEC Filing

Inrig Jula 4

Accession 0001415889-25-019108

CIK 0001438533other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 5:28 PM ET

Size

5.3 KB

Accession

0001415889-25-019108

Insider Transaction Report

Form 4
Period: 2025-07-01
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
  • Sale

    Common Stock

    2025-07-01$14.65/sh815$11,94088,787 total
Footnotes (1)
  • [F1]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in February 2025.

Issuer

Travere Therapeutics, Inc.

CIK 0001438533

Entity typeother

Related Parties

1
  • filerCIK 0001902368

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 5:28 PM ET
Size
5.3 KB